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Background
Chronic infantile neurological cutaneous and articular
syndrome (CINCA), also known as neonatal-onset mul-
tisystem inflammatory disease (NOMID) is characterized
by urticarial rash, neurological manifestations and
arthropathy. This dominantly-inherited systemic autoin-
flammatory disease is provoked by heterozygous germ-
line gain-of-function NLRP3 mutations, although
conventional genetic analyses failed to detect disease-
causing mutations in approximately 40% of patients. In
these patients, NLRP3 somatic mosaicism was reported
to be disease-causing and recently, high incidence of
NLRP3 somatic mosaicism was reported in the interna-
tional study. In the study, subcloning and Sanger
sequencing were used to detect NLRP3 somatic mosai-
cism. However, the method requires time-consuming
sample preparation and enormous cost to run enough
sequencing per sample to detect low-level somatic
mosaicism.
Aim
To reduce the work and cost for detecting the low-level
NLRP3 somatic mosaicism, we performed next-genera-
tion sequencing on “mutation-negative” CINCA/
NOMID patients.
Methods
Genomic DNA was isolated from previously reported
Japanese CINCA/NOMID patients with NLRP3 somatic
mosaicism, NLRP3 heterozygous mutations, healthy
donors, and new “mutation-negative” CINCA/NOMID
patients. All 9 NLRP3 exons were amplified by using
specially designed primers in 2nd step PCR. We used
the Roche GS-FLX 454 Genome Sequencer which had
longer read length than other widely used next-genera-
tion sequencers.
Results
NLRP3 somatic mosaicism was identified in all pre-
viously reported Japanese CINCA/NOMID patients with
NLRP3 somatic mosaicism, and 4 out of the new 10
“mutation-negative” CINCA/NOMID patients. No
mosaicism was detected in 50 healthy donors.
Conclusions
Somatic mutations of NLRP3 can be identified by using
next-generation sequencing with reduced workload and
costs.
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